Abstract: Methods of treating cystic fibrosis transmembrane conductance regulator (CFTR)-mediated disease, such as cystic fibrosis, in patients with residual function mutations.

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.

Abstract: Disclosed is a compound, a preparation method and use thereof. The compound of the application is prepared by extracting and separating from Limax, and has significant effects on physiological or psychological dependent detoxification or detoxication. Pharmacological tests have proved that the compound has a significant inhibitory effect on withdrawal jumping symptoms in morphine-dependent animals 1 hour after intragastric administration, and still shows an inhibitory trend after 3 hours. The compound has potential application value in the preparation of medicines, health food, and food for detoxification, detoxication, or similar drug-dependent treatment.

Abstract: A trichlorogermanide of formula (I): [R4N]/[R4P]Cl[GeCl3] (I), where R is Me, Et, iPr, nBu, or Ph, tris(trichlorosilyl)germanide of formula (II): [R4N]/[R4P][Ge(SiCl3)3] (II), where R is Me, Et, iPr, nBu, or Ph, a tris(trichlorosilyl)germanide adduct of GaCl3 of formula (III): [Ph4P][Ge(SiCl3)3*GaCl3], and a tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV): [Ph4P][Ge(SiCl3)3*BBr3]. Also, methods for preparing the trichlorogermanides of formula (I), the tris(trichlorosilyl)germanide of formula (II), the tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV).

Abstract: A composition comprises one or more trimesic acid derivatives of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a composition as described above and a polyolefin polymer. The polymer compositions containing a trimesic acid derivative of Formula (I) exhibit very low haze levels and minimal extraction of the trimesic acid derivative.

Abstract: The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.

Abstract: The present disclosure is directed to hydrosilyl amines and fluorosilyl amines and methods of making the same.

Abstract: An organic electroluminescence device according to embodiments of the present disclosure includes a first electrode, a second electrode opposite the first electrode, and at least one organic layer between the first electrode and the second electrode, wherein the at least one organic layer includes an amine compound represented by Formula 1, and HT in Formula 1 includes a pyridoindole moiety represented by Formula 2. Improved device efficiency and life characteristics may be achieved when the amine compound represented by Formula 1 is included in the organic electroluminescence device.

Abstract: Platinum complexes having benzyl-based diphosphine ligands for the catalysis of the alkoxycarbonylation of ethylenically unsaturated compounds.

Abstract: A process is disclosed for making CF3CF?CHF. The process involves reacting CF3CClFCCl2F with H2 in a reaction zone in the presence of a catalyst to produce a product mixture comprising CF3CF?CHF. The catalyst has a catalytically effective amount of palladium supported on a support selected from the group consisting of alumina, fluorided alumina, aluminum fluoride and mixtures thereof and the mole ratio of H2 to CF3CClFCCl2F fed to the reaction zone is between about 1:1 and about 5:1. Also disclosed are azeotropic compositions of CF3CClFCCl2F and HF and azeotropic composition of CF3CHFCH2F and HF.

Abstract: Process for preparing polysulfane silanes of the formula I (R1O)3-mR2mSi—R3—Sx—R3—SiR2m(OR1)3-m??I, by reaction of silane of the formula II (R1O)3-mR2mSi—R3-Hal??II, with one or more metal sulfides of the formula III Me(SH)f and/or Me3-fSx-y??III, optionally in the presence of one or more salts of monohydric or polyhydric acids, with the optional addition of y mol of sulfur in aqueous R1—OH solution, wherein the water content of the aqueous R1—OH solution is 5% to 40% by weight, wherein a. the process stream from the reaction of silane of the formula II with one or more metal sulfides of the formula III, optionally in the presence of one or more salts and optionally with the addition of sulfur, in aqueous R1—OH solution, comprising polysulfane silanes of the formula I, silane of the formula II, metal sulfides of the formula III, solvent R1—OH, water and process salts, is combined with the wash solution from step d, comprising solvent R1—OH, water and polysulfane silanes of the formula I, b.

Abstract: Provided are an organometallic compound represented by Formula 1 and an organic light-emitting device including the same. The organic light-emitting device includes a first electrode; a second electrode facing the first electrode; an organic layer between the first electrode and the second electrode and including an emission layer; and at least one organometallic compound represented by Formula 1.

Abstract: A condensed cyclic compound represented by Formula 1 and including 9 to 60 aromatic rings: A is a group represented by Formula 10, n is selected from 1, 2, 3, and 4, L is hydrogen, a single bond or a linking group, and when n is 1, p is selected from 1, 2, 3, and 4, and q is selected from 1, 2, 3, and 4, wherein Formula 10 is the same as described in the specification.

Abstract: A 1,1,1-tris(organoamino)disilane compound and a method of preparing the 1,1,1-tris(organoamino)disilane compound are disclosed. The method comprises aminating a 1,1,1-trihalodisilane with an aminating agent comprising an organoamine compound to give a reaction product comprising the 1,1,1-tris(organoamino)disilane compound, thereby preparing the 1,1,1-tris(organoamino)disilane compound. A film-forming composition is also disclosed. The film-forming composition comprises the 1,1,1-tris(organoamino)disilane compound. A film formed with the film-forming composition, and a method of forming the film, are also disclosed. The method of forming the film comprises subjecting the film-forming composition comprising the 1,1,1-tris(organoamino)disilane compound to a deposition condition in the presence of a substrate, thereby forming the film on the substrate.

Abstract: A trichlorogermanide of formula (I): [R4N]/[R4P]Cl[GeCl3] (I), where R is Me, Et, iPr, nBu, or Ph, tris(trichlorosilyl)germanide of formula (II): [R4N]/[R4P][Ge(SiCl3)3] (II), where R is Me, Et, iPr, nBu, or Ph, a tris(trichlorosilyl)germanide adduct of GaCl3 of formula (III): [Ph4p][Ge(SiCl3)3*GaCl3], and a tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV): [Ph4P[]Ge(SiCl3)3*BBr3]. Also, methods for preparing the trichlorogermanides of formula (I), the tris(trichlorosilyl)germanide of formula (II), the tris(trichlorosilyl)germanide adduct of BBr3 of formula (IV).

Abstract: The disclosure relates to dicarbonyl complexes of ruthenium and osmium with bi- and tridentate nitrogen and phosphine ligands. The disclosure relates to methods for preparing these complexes and the use of these complexes, isolated or prepared in situ, as catalysts for reduction reactions of ketones and aldehydes both via transfer hydrogenation or hydrogenation with hydrogen.

Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.

Abstract: An object of the present invention is to provide an organic EL element that has (1) high light emission efficiency and high power efficiency, (2) a low light-emission start voltage, (3) a low actual driving voltage, and (4) an especially long lifespan. According to the present invention, provided is an organic electroluminescent element, or organic EL element, having at least an anode, a hole injection layer, a first hole transport layer, a second hole transport layer, a light emitting layer, an electron transport layer, and a cathode, in this order, wherein the second hole transport layer contains an arylamine compound represented by the general formula (1) below, and the electron transport layer contains a pyrimidine derivative represented by the general formula (2) below. Note that A in the general formula (2) represents a monovalent group represented by the structural formula (3) below.

Abstract: Methods are provided for synthesizing W(IV) beta-diketonate precursors. Additionally, methods are provided for forming W containing thin films, such as WS2, WNx, WO3, and W via vapor deposition processes, such as atomic layer deposition (ALD) type processes and chemical vapor deposition (CVD) type processes. Methods are also provided for forming 2D materials containing W.

Abstract: Provided is 2-(4-diethylamino)butylmalonic acid-(1R,2R)-(?)-1,2-cyclohexanediamine platinum(II) phosphate having high solubility, low hygroscopicity, and high stability and being suitable for preparing into various antitumor drug preparations. Also provided is a preparation method for amorphous 2-(4-diethylamino)butylmalonic acid-(1R,2R-)-1,2-cyclohexanediamine platinum(II) phosphate. The method is simple to operate and is suitable for industrial implementation.